The Dulai lab focuses on novel clinical trial designs, biomarker discovery, and personalized medicine. As the Director of GI Clinical Trials Dr. Dulai oversees a robust clinical trial program that spans both industry and federally sponsored trials. He serves on several steering committees for phase 2/3 drug development programs in inflammatory bowel disease (IBD), and is the principal investigator for an NIDDK sponsored U01 clinical trial for hyperbaric oxygen therapy in acute severe ulcerative colitis. His research program has helped to define emerging end-points for clinical trials in IBD with the development of novel patient reported outcome measurement tools, endoscopic indices, and considerations for integration of biomarkers into clinical trial designs. The Dulai lab biomaker discovery program oversees a large human translational biobanking program in GI (Digestive Health Foundation Biorepository) and his wet lab is fully equppied with high-throughput state-of-the-art spatial biology and single-cell sequencing instruments to study immune-epithelial-microbe interactions at the gut interface. He has successfully integrated this technology into his NIDDK U01 clinical trial program and a multi-PI NIDDK R01 to study neutrophil specific mechanisms of treatment resistance in IBD. He now serves as a Core Director for an NIAID sponsored U19 where he will oversee the Technology Core and provide a multi-omic spatial and single-cell approach to advance our understanding of the role of neutrophil pathobiology in human lung and airway diseases. As Director of Precision Medicine in GI, he has worked to further harmonize his efforts in clinical trials and biomarker discovery to not only define mechanisms of treatment resistance, but also develop novel prediction models for point-of-care decision support. He has built several clinical decision support tools for biologics in IBD and his web platform (www.CDSTforIBD.com) is endorsed by the American Gastroenterology Association.